Clinical Efficacy of Ginkgo Biloba Extract in the Treatment of Alzheimer's Disease
NCT ID: NCT03090516
Last Updated: 2019-08-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2/PHASE3
240 participants
INTERVENTIONAL
2016-08-10
2020-03-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment for Early Memory Loss
NCT00042172
Preventing Cognitive Decline With Alternative Therapies
NCT00010920
Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease
NCT02787746
Evaluate the Safety and Efficacy of AD-35 Tablet in Subjects With Mild to Moderate Alzheimer's Disease
NCT03790982
Study on Ginkgo Biolba Extract Fifty and Mild Cognitive Impairment Associated With CSVD
NCT06495476
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A ：Donepezil
A：People are randomly divided into three groups according to the educational conditiono，gender and age.
Donepezil
Arm A：Aricept 5mg/day
Arm B ：Donepezil and Ginkgo biloba dispersible tablets
B：People are randomly divided into three groups according to the educational conditiono，gender and age.
Ginkgo biloba dispersible tablets and Donepezil
Arm B：Ginkgo biloba dispersible tablets，0.15g at a time， three times a day.Aricept 5mg/day.
Arm C：Ginkgo biloba dispersible tablets
C：People are randomly divided into three groups according to the educational conditiono，gender and age.
Ginkgo biloba dispersible tablets
Arm C：Ginkgo biloba dispersible tablets，0.15g at a time， three times a day.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ginkgo biloba dispersible tablets
Arm C：Ginkgo biloba dispersible tablets，0.15g at a time， three times a day.
Donepezil
Arm A：Aricept 5mg/day
Ginkgo biloba dispersible tablets and Donepezil
Arm B：Ginkgo biloba dispersible tablets，0.15g at a time， three times a day.Aricept 5mg/day.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Improved Hachinski ischemic scale score \<4
3. All patients underwent head CT and / or MRI examinations and laboratory tests to rule out other causes of dementia
4. MMSE(High school≤24,Primary school≤20;illiteracy≤17)
5. CDR 1-2
6. The subjects and nurses signed informed consent, and the nursing staff were able to take responsibility for the supervision of the participants
7. The subjects were stable
8. Cooperate, willing to complete all parts of the research, and have the ability to complete the study alone or with the help of the nursing staff
9. To cooperate with the study, do not live alone, such as living alone should keep in touch with the nurse every day.
Exclusion Criteria
2. According to NINDS-AIREN standard (Roman GC et al 1993) is currently diagnosed as possible vascular dementia
3. Improved Hachinski ischemic scale score（MHIS）≥4
4. Diagnosis of severe depression, schizophrenia, and other major neurodegenerative disorders, according to the DSM-IV axis
5. Neurological or other medical disorders that affect the function of the central nervous system,like Moderate anemia,Vitamin B12 or folic acid deficiency, et al. Not with the cognitive function examination (including blindness, deafness, severe language disorders).
50 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The First Affiliated Hospital with Nanjing Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ting Wu
Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ting Wu
Role: STUDY_DIRECTOR
The First Affiliated Hospital with Nanjing Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ting Wu
Nanjing, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Ginkgo biloba
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.